Recent Updates
Recently added Catalysts
NKTX Positive Sentiment

Nkarta to Participate in March Investor Conferences

Friday, February 27, 2026 BiopharmaWatch Research 1 min read
Add on Google
Key Takeaway: Nkarta, Inc. announced its participation in two upcoming investor conferences in March 2026. The events include the TD Cowen 46th Annual Health Care Conference and the Leerink Global Healthcare Conference, where Nkarta will host fireside chats. Both events will be available via webcast, enhancing accessibility for investors.
Price reaction · baseline $2.62 (2026-02-26 close) · hit pre-market · clean, no other NKTX news in the window
day 0 close · peak
+3.1%

Market Sentiment Analysis

POSITIVE FACTORS

  • Nkarta is actively engaging with investors through conferences.
  • The company is advancing innovative NK cell therapies.
  • Webcasts of the events will be available for broader access.

BiopharmaWatch Analysis

From our catalyst data and publicly available data · not financial advice
Best trade, last catalyst
+124%
120-day peak, hindsight
Typical move
7.6%
average across 3 past catalysts
Cash runway
~22 mo
Low dilution risk
Lead asset
NKX101- CAR NK cell therapy
Phase 1 · Relapsed/Refractory AML

Full Press Release Details

SOUTH SAN FRANCISCO, Calif., Feb. 27, 2026 (GLOBE NEWSWIRE) -- Nkarta, Inc. (Nasdaq: NKTX), a clinical-stage biopharmaceutical company developing engineered natural killer (NK) cell therapies to treat autoimmune diseases, today announced its participation in the following investor conferences:
March 2, 2026TD Cowen 46th Annual Health Care ConferenceBoston, MA9:10 a.m. EST – fireside chatMarch 10, 2026Leerink Global Healthcare ConferenceMiami, FL10:40 a.m. EDT – fireside chatA simultaneous webcast of both events will be available on theInvestors sectionof Nkarta’s website, and a replay will be archived on the website for approximately 90 days.
About NkartaNkarta is a clinical-stage biotechnology company advancing the development of allogeneic, off-the-shelf natural killer (NK) cell therapies for autoimmune diseases. By combining its cell expansion and cryopreservation platform with proprietary cell engineering technologies, Nkarta is building a pipeline of future cell therapies engineered for deep therapeutic activity and intended for broad access in the outpatient treatment setting. For more information, please visit the company’s website atwww.nkartatx.com.

Nkarta Media/Investor Contact:Nadir MahmoodNkarta, Inc.nmahmood@nkartatx.com

Frequently Asked Questions

What conferences will Nkarta participate in?

Nkarta will participate in the TD Cowen 46th Annual Health Care Conference and the Leerink Global Healthcare Conference.

When is Nkarta's fireside chat at the TD Cowen conference?

Nkarta's fireside chat at the TD Cowen conference is scheduled for March 2, 2026, at 9:10 a.m. EST.

How can investors access the conference webcasts?

Investors can access the webcasts of both conferences on Nkarta's website.

What is Nkarta developing?

Nkarta is developing engineered natural killer (NK) cell therapies for autoimmune diseases.

ShareAdd on Google
Tags: NKTX Viatris Investor Conferences Healthcare Nkarta NK cell therapies investor conferences biopharmaceutical clinical-stage
Last updated: Feb 27, 2026

Biotech snapshot

Cash runway
$183M liquidity · $8M/mo burn
~22 mo
Low dilution risk
Lead asset
NKX101- CAR NK cell therapyPhase 1
Relapsed/Refractory AML →

Catalyst track record

+124%
best trade around NKTX's last catalyst

Peak hindsight return over a 120-day window, across 3 tracked FDA/PDUFA catalysts for NKTX.

See every catalyst's timing & PoA →